Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.561, 2008-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Cancer treatment in clinical trials not so costly after all?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 279, 2000-01 ,pp. :
Access to resources
Recommend
IFN- cost effective for MS after all?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. :
IFN- cost effective for MS after all?
Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. :
Is there still a place for high-dose methotrexate in paediatric ALL?
Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. :
Does `NICE blight' exist, and if so, why?
By Haycox Alan
PharmacoEconomics, Vol. 26, Iss. 12, 2008-01 ,pp. :